Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Breaking Down CARTITUDE-4: Survival in High-Risk Patients, Extramedullary Disease, and Prior 1 to 3 Lines of Therapy

July 31st 2025

Panelists discuss how the CARTITUDE-4 subgroup analysis demonstrated that cilta-cel provides significant progression-free and overall survival advantages over standard of care across all patient subgroups, including those with high-risk cytogenetics, extramedullary disease, and varying numbers of prior therapy lines.

Trispecific Antibodies, Novel CAR T-Cell Therapies Signal Progress in R/R Myeloma

July 30th 2025

Joshua Richter, MD, outlines how trispecific antibodies and novel CAR T-cell therapies are shaping the 2025 myeloma landscape and improving patient access.

Five Under 5: Top Oncology Videos for the Week of 7/20

July 27th 2025

The top 5 OncLive videos of the week cover insights in multiple myeloma, breast cancer, melanoma, and CLL/SLL.

Dr Landgren on Considerations Surrounding the Current Treatment Paradigm for Smoldering Multiple Myeloma

July 26th 2025

C. Ola Landgren, MD, PhD, discusses the current treatment paradigm for patients with smoldering multiple myeloma.

Dr Mewawalla on the Real-World Roles of Cilta-Cel and Ide-Cel in R/R Myeloma

July 24th 2025

Prerna Mewawalla, MD, explains the roles of cilta-cel and ide-cel in clinical practice for the treatment of relapsed/refractory multiple myeloma.

Belantamab Mafodotin Combos Receive EU, Canadian Approval for R/R Myeloma

July 24th 2025

The European Commission and Health Canada have approved belantamab mafodotin-based combinations for relapsed/refractory multiple myeloma.

Subcutaneous Daratumumab Receives European Commission Approval in Smoldering Myeloma

July 23rd 2025

Subcutaneous daratumumab received EU approval for the treatment of patients with smoldering multiple myeloma at high risk of developing multiple myeloma.

Dr Pan on Late-Onset Toxicities Associated With CAR T-Cell Therapy in Multiple Myeloma

July 22nd 2025

Darren Pan, MD, outlines late-onset toxicities related to CAR T-cell therapies in multiple myeloma and their management.

Positioning CAR T in Early Relapse MM

July 22nd 2025

Panelists discuss how chimeric antigen receptor (CAR) T-cell therapy is increasingly being used earlier in the treatment paradigm rather than in the late-stage, with better disease control prior to infusion leading to improved outcomes and reduced toxicity, particularly for high-risk patients or those with functional high-risk disease relapsing sooner than expected.

Examining CAR T Eligibility in Clinical Practice in R/R MM

July 22nd 2025

Panelists discuss how approximately 75% to 80% of patients with multiple myeloma are eligible for chimeric antigen receptor (CAR) T-cell therapy at some point during their care, with eligibility determined by safety criteria including organ function and comorbidities, logistical feasibility, and efficacy considerations rather than direct comparisons to autologous transplant.

Sequencing Considerations Are Important for T-Cell Redirection Therapies in Relapsed/Refractory Myeloma

July 21st 2025

Darren Pan, MD, highlighted key sequencing strategies for T-cell redirection therapy in relapsed/refractory multiple myeloma.

The OncFive: Top Oncology Articles for the Week of 7/13

July 19th 2025

Glofitamab received a CRL from the FDA in R/R DLBCL, ODAC voted against belantamab mafodotin in R/R multiple myeloma, and more.

FDA’s ODAC Votes Against Risk:Benefit Profiles of Belantamab Mafodotin Combos in R/R Myeloma

July 17th 2025

The FDA’s ODAC voted against the risk/benefit profiles of belantamab mafodotin–based combinations in relapsed/refractory multiple myeloma.

Cilta-Cel Data Set a High Bar for Anito-Cel in Relapsed/Refractory Myeloma

July 15th 2025

Darren Pan, MD, discusses updates regarding cilta-cel and anito-cel for the treatment of patients with relapsed/refractory multiple myeloma.

Dr Krishnan on Elranatamab Plus Daratumumab/Lenalidomide in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

July 15th 2025

Amrita Krishnan, MD, discusses data for elranatamab plus daratumumab and lenalidomide in newly diagnosed, transplant-ineligible multiple myeloma.

Dr Pan on the Novel Therapy Anito-Cel in Relapsed/Refractory Myeloma

July 10th 2025

Darren Pan, MD, highlights the novelty of anito-cel in relapsed/refractory multiple myeloma, including the difference in safety profile vs cilta-cel.

Dr Chari on the Evolving Determination of Transplant Eligibility in Multiple Myeloma

July 9th 2025

Ajai Chari, MD, expands on the evolving debate surrounding transplant eligibility determination in newly diagnosed multiple myeloma.

Long-Term Remission, OS With Cilta-Cel Set New Benchmarks for Survival Outcomes in R/R Myeloma

July 9th 2025

Peter Voorhees, MD, highlights 5-year follow-up data from the CARTITUDE-1 trial evaluating cilta-cel in relapsed/refractory multiple myeloma.

Dr Voorhees on the Clinical Implications of Cilta-Cel in Relapsed/Refractory Myeloma

July 9th 2025

Peter Voorhees, MD, details the clinical implications of cilta-cel for the treatment of patients with relapsed/refractory multiple myeloma.

Updated EHA-EMN Guidelines Include Melphalan Flufenamide for R/R Myeloma

July 8th 2025

The EHA-EMN guidelines now include melphalan flufenamide for certain patients with relapsed/refractory multiple myeloma.